Zentalis Pharmaceuticals, Inc.
ZNTLHealthcareNASDAQBiotechnology · Last scanned Sep 8, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Zentalis Pharmaceuticals, Inc. focuses on Biotechnology services and products. Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. At a $377.7M market cap, Zentalis Pharmaceuticals, Inc. ranks as a small-cap company within healthcare. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types.
Market Cap
$377.7M
Beta
1.86
P/E (TTM)
—
P/E (Fwd)
-2.21
EPS (TTM)
$-1.96
EPS (Fwd)
$-1.81
ROE
-66.8%
ROA
-33.1%
Cash
$174.6M
Total Debt
$37.7M
Free CF
-$79.5M
52W Change
149.4%
Annual Financials
Cash vs Debt
Where ZNTL stands vs its 150-day and 200-day moving averages
As of the August 27, 2026 close, ZNTL finished 6.58% above its 150-day moving average ($3.65) and 22.71% above its 200-day moving average ($3.17). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ZNTL overbought or oversold?
At the August 27, 2026 close, ZNTL's RSI(14) was 26.3, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $174.6M in cash and $37.7M in debt, ZNTL maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$79.5M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -66.8%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With a beta above 1.5, ZNTL tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. With cash comfortably exceeding debt, ZNTL has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing ZNTL.